Dissecting Integrin Expression and Function on Memory B Cells in Mice and Humans in Autoimmunity.

Area of Science:

• Immunology
• Cell Biology
• Molecular Biology

Background:

• Immunological memory, crucial for lifelong pathogen protection, relies on long-lived memory B cells (MBCs) residing in the spleen.
• Integrins are known to regulate lymphocyte survival and trafficking, but their specific role in MBC retention within secondary lymphoid organs remains unclear.
• Differences in adhesion capacity to ICAM-1 and VCAM-1 among B cell subsets are not fully established.

Purpose of the Study:

• To investigate the role of integrins LFA-1 and VLA-4 in the retention and adhesion of memory B cells (MBCs) in the spleen.
• To determine if MBCs exhibit distinct integrin expression and adhesion properties compared to other B cell subsets.
• To examine integrin expression in MBCs from both healthy individuals and patients with autoimmune diseases like rheumatoid arthritis.

Main Methods:

• Utilized an autoimmune mouse model with abundant MBCs to analyze integrin expression (LFA-1, VLA-4) on different B cell subsets.
• Administered in vivo blockade of VLA-4 and LFA-1 to assess their impact on MBC localization in mice.
• Analyzed integrin expression and adhesion capacity of MBCs from human peripheral blood, spleens, and tonsils of healthy donors and rheumatoid arthritis patients.

Main Results:

• MBCs in mice and humans exhibit the highest expression of integrins LFA-1 and VLA-4 among B cell populations.
• In vivo blockade of VLA-4 (alone or with LFA-1) induced MBC release from the spleen into the bloodstream.
• MBCs demonstrated a greater adhesion capacity to ICAM-1 and VCAM-1 compared to naïve B cells.

Conclusions:

• Integrins LFA-1 and VLA-4 are selectively utilized by MBCs for their localization and adhesion within secondary lymphoid organs in both mice and humans.
• These findings provide critical insights into the mechanisms governing MBC retention and trafficking, relevant for understanding immune memory and autoimmune diseases.
• Altered integrin expression and activation in MBCs of rheumatoid arthritis patients, particularly those on anti-TNF therapy, warrants further investigation.